Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Originally published as JCO Early Release 10.1200/JCO.2007.14.3396 on October 22 2007

Journal of Clinical Oncology, Vol 26, No 1 (January 1), 2008: pp. 132-149
© 2008 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Publisher's Note
Right arrow Addendum
Right arrow Erratum (v26,p1192)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rizzo, J. D.
Right arrow Articles by Lichtin, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rizzo, J. D.
Right arrow Articles by Lichtin, A. E.
Related Articles
Right arrowRelated Correspondence

ASCO SPECIAL ARTICLE

Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update

J. Douglas Rizzo, Mark R. Somerfield, Karen L. Hagerty, Jerome Seidenfeld, Julia Bohlius, Charles L. Bennett, David F. Cella, Benjamin Djulbegovic, Matthew J. Goode, Ann A. Jakubowski, Mark U. Rarick, David H. Regan, Alan E. Lichtin

Medical College of Wisconsin, Milwaukee, WI; American Society of Clinical Oncology, Alexandria, VA; Blue Cross and Blue Shield Association; Northwestern University, Chicago; Evanston Northwestern Healthcare, Evanston, IL; University Hospital of Cologne, Cologne, Germany; H. Lee Moffitt Cancer Center, Tampa, FL; Patient Representative, Mesa, AZ; Memorial Sloan-Kettering Cancer Center, New York, NY; NW Kaiser Permanente, US Oncology, Portland, OR; and Cleveland Clinic Foundation, Cleveland, OH

Corresponding author: American Society of Clinical Oncology, 1900 Duke St, Suite 200, Alexandria, VA 22314; e-mail: guidelines{at}asco.org

Purpose: To update the American Society of Clinical Oncology/American Society of Hematology (ASCO/ASH) recommendations for the use of epoetin. The guideline was expanded to address use of darbepoetin and thromboembolic risk associated with these agents.

Method: An Update Committee ("Committee") reviewed and analyzed data published since 2002 through July 2007. MEDLINE and the Cochrane Collaboration Library databases were searched.

Recommendations: For patients with chemotherapy-associated anemia, the Committee continues to recommend initiating an erythropoiesis-stimulating agent (ESA) as hemoglobin (Hb) approaches, or falls below, 10 g/dL, to increase Hb and decrease transfusions. ESA treatment continues to be recommended for patients with low-risk myelodysplasia for similar reasons. There is no evidence showing increased survival as a result of ESA treatment. Conclusive evidence is lacking that, absent clinical circumstances necessitating earlier treatment, initiating ESAs at Hb levels greater than 10 g/dL either spares more patients from transfusion or substantially improves their quality of life.

Starting doses and dose modifications based on response or lack thereof should follow the package insert. Continuing ESAs beyond 6 to 8 weeks in the absence of response, assuming appropriate dose increase has been attempted in nonresponders as per US Food and Drug Administration–approved labeling, does not seem to be beneficial, and ESA therapy should be discontinued. The Committee recommends monitoring iron stores and supplementing iron intake for ESA-treated patients. ESAs should be used cautiously with chemotherapy, or in clinical states, associated with elevated risk for thromboembolic complications. The Committee also cautions against ESA use for patients with cancer who are not receiving chemotherapy, since recent trials report increased thromboembolic risks and decreased survival under these circumstances.

published online ahead of print at www.jco.org on October 22, 2007.

Approved by the ASCO Board of Directors on August 15, 2007. Approved by the Executive Committee of ASH on August 14, 2007.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This guideline was developed through a collaboration between the American Society of Clinical Oncology and the American Society of Hematology and has been published jointly by invitation and consent in both the Journal of Clinical Oncology and Blood. Copyright © 2007 American Society of Clinical Oncology and American Society of Hematology. All rights reserved. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission by the American Society of Clinical Oncology or the American Society of Hematology.


Related Correspondence

  • Reconsideration of American Society of Clinical Oncology/American Society of Hematology Erythropoiesis-Stimulating Agent Guidelines
    Nevin Murray and Richard Klasa
    JCO 2008 26: 3096-3097 [Full Text]
  • Erythropoiesis-Stimulating Agents in Cancer
    Murat O. Arcasoy
    JCO 2008 26: 3097-3098 [Full Text]


This article has been cited by other articles:


Home page
JCOHome page
N. Murray and R. Klasa
Reconsideration of American Society of Clinical Oncology/American Society of Hematology Erythropoiesis-Stimulating Agent Guidelines
J. Clin. Oncol., June 20, 2008; 26(18): 3096 - 3097.
[Full Text] [PDF]


Home page
JCOHome page
M. O. Arcasoy
Erythropoiesis-Stimulating Agents in Cancer
J. Clin. Oncol., June 20, 2008; 26(18): 3097 - 3098.
[Full Text] [PDF]


Home page
JCOHome page
J. D. Rizzo, M. R. Somerfield, K. L. Hagerty, J. Seidenfeld, J. Bohlius, C. L. Bennett, D. F. Cella, B. Djulbegovic, M. J. Goode, A. A. Jakubowski, et al.
In Reply
J. Clin. Oncol., June 20, 2008; 26(18): 3098 - 3100.
[Full Text] [PDF]


Home page
The OncologistHome page
D. Gordon, G. Nichols, A. Ben-Jacob, D. Tomita, T. Lillie, and C. Miller
Treating Anemia of Cancer with Every-4-Week Darbepoetin Alfa: Final Efficacy and Safety Results from a Phase II, Randomized, Double-Blind, Placebo-Controlled Study
Oncologist, June 1, 2008; 13(6): 715 - 724.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
C. L. Bennett, S. M. Silver, B. Djulbegovic, A. T. Samaras, C. A. Blau, K. J. Gleason, S. E. Barnato, K. M. Elverman, D. M. Courtney, J. M. McKoy, et al.
Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia
JAMA, February 27, 2008; 299(8): 914 - 924.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online